BridgeBio Pharma (NASDAQ:BBIO) Issues Earnings Results, Beats Expectations By $0.04 EPS

Share on StockTwits

BridgeBio Pharma (NASDAQ:BBIO) posted its quarterly earnings data on Thursday. The company reported ($0.51) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.04, Yahoo Finance reports. The firm had revenue of $26.74 million during the quarter.

Shares of BBIO stock opened at $27.06 on Friday. The stock has a 50-day moving average of $20.94. BridgeBio Pharma has a one year low of $17.61 and a one year high of $32.94.

BBIO has been the topic of a number of research analyst reports. BMO Capital Markets initiated coverage on shares of BridgeBio Pharma in a research note on Monday, July 22nd. They issued an “outperform” rating and a $49.00 target price on the stock. Piper Jaffray Companies dropped coverage on shares of BridgeBio Pharma in a research note on Friday, October 18th. Goldman Sachs Group initiated coverage on shares of BridgeBio Pharma in a research note on Monday, July 22nd. They issued a “buy” rating and a $42.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of BridgeBio Pharma in a research note on Monday, July 22nd. They issued a “buy” rating and a $38.00 target price on the stock. Finally, Svb Leerink initiated coverage on shares of BridgeBio Pharma in a research note on Monday, July 22nd. They issued an “outperform” rating and a $34.00 target price on the stock. One investment analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $40.13.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.

Further Reading: Understanding debt-to-equity ratio in fundamental analysis

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.